Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review

BMC Medical Research Methodology

Volumn 11, Issue , 2011, Pages

  Langham, Sue ^a   Langham, Julia ^b   Goertz, Hans Peter ^c   Ratcliffe, Mark ^a  

^a PHMR LTD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; COHORT ANALYSIS; ECONOMICS; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; TREATMENT OUTCOME;

ADULT; ARTHRITIS, PSORIATIC; COHORT STUDIES; DATA COLLECTION; HEALTH CARE COSTS; HUMANS; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 79953182027     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-11-32     Document Type: Article

References (98)

1. Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: a Multicenter Cross-Sectional Study in Germany. M Augustin K Kruger MA Radtke I Schwippl K Reich, Dermatology 2008 216 4 366 72 10.1159/000119415 18319601 (Pubitemid 351630108)
2. A Longitudinal Study of the Effect of Disease Activity and Clinical Damage on Physical Function Over the Course of Psoriatic Arthritis: Does the Effect Change Over Time? JA Husted BD Tom VT Farewell CT Schentag DD Gladman, Arthritis Rheum 2007 56 3 840 9 10.1002/art.22443 17328058 (Pubitemid 46399432)
3. Impact of Psoriasis on Health-Related Quality of Life Decreases Over Time: an 11-Year Prospective Study. J Unaeze T Nijsten A Murphy C Ravichandran RS Stern, J Invest Dermatol 2006 126 7 1480 9 10.1038/sj.jid.5700229 16575395
4. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated With Widespread Treatment Dissatisfaction. RS Stern T Nijsten SR Feldman DJ Margolis T Rolstad, J Investig Dermatol Symp Proc 2004 9 2 136 9 10.1046/j.1087-0024.2003.09102.x 15083780 (Pubitemid 38457271)
5. Determinants of Quality of Life in Patients With Psoriasis: a Study From the US Population. JM Gelfand SR Feldman RS Stern J Thomas T Rolstad DJ Margolis, J Am Acad Dermatol 2004 51 5 704 8 10.1016/j.jaad.2004.04.014 15523347 (Pubitemid 39516879)
6. Psychological Distress Impairs Clearance of Psoriasis in Patients Treated With Photochemotherapy. DG Fortune HL Richards B Kirby K McElhone T Markham S Rogers CJ Main CE Griffiths, Arch Dermatol 2003 139 6 752 6 10.1001/archderm. 139.6.752 12810506 (Pubitemid 36705942)
7. An Italian Study on Psoriasis and Depression. M Esposito R Saraceno A Giunta M Maccarone S Chimenti, Dermatology 2006 212 2 123 7 10.1159/000090652 16484818 (Pubitemid 43260727)
8. Role of Depression in Quality of Life for Patients With Psoriasis. JM Schmitt DE Ford, Dermatology 2007 215 1 17 27 10.1159/000102029 17587835 (Pubitemid 46976010)
9. Psoriasis Causes As Much Disability As Other Major Medical Diseases. SR Rapp SR Feldman ML Exum AB Fleischer Jr DM Reboussin, J Am Acad Dermatol 1999 41 3 Pt 1 401 7 10.1016/S0190-9622(99)70112-X 10459113 (Pubitemid 29418506)
10. Work Limitations and Productivity Loss Are Associated With Health-Related Quality of Life but Not With Clinical Severity in Patients With Psoriasis. JM Schmitt DE Ford, Dermatology 2006 213 2 102 10 10.1159/000093848 16902286 (Pubitemid 44215193)
11. Moderate and Severe Plaque Psoriasis: Cost-of-Illness Study in Italy. G Colombo G Altomare K Peris P Martini G Quarta M Congedo A Costanzo A Di Cesare E Lapucci S Chimenti, Ther Clin Risk Manag 2008 4 2 559 68 18728854 (Pubitemid 351712015)
12. The Direct Cost of Care for Psoriasis and Psoriatic Arthritis in the United States. HS Javitz MM Ward E Farber L Nail SG Vallow, J Am Acad Dermatol 2002 46 6 850 60 10.1067/mjd.2002.119669 12063481
13. Cost-of-Illness in Patients With Moderate and Severe Chronic Psoriasis Vulgaris in Germany. K Berger B Ehlken B Kugland M Augustin, J Dtsch Dermatol Ges 2005 3 7 511 8 10.1111/j.1610-0387.2005.05729.x 15967010 (Pubitemid 40942633)
14. Excess Mortality Related to Alcohol and Smoking Among Hospital-Treated Patients With Psoriasis. K Poikolainen J Karvonen E Pukkala, Arch Dermatol 1999 135 12 1490 3 10.1001/archderm.135.12.1490 10606054
15. Malignant Tumours and Psoriasis: a Follow-Up Study. G Frentz JH Olsen, Br J Dermatol 1999 140 2 237 42 10.1046/j.1365-2133.1999.02655.x 10233215 (Pubitemid 29111349)
16. Cardiovascular Morbidity in Psoriatic Arthritis. DD Gladman M Ang L Su BD Tom CT Schentag VT Farewell, Ann Rheum Dis 2009 68 7 1131 5 10.1136/ard.2008.094839 18697777
17. The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study. JM Gelfand AB Troxel JD Lewis SK Kurd DB Shin X Wang DJ Margolis BL Strom, Arch Dermatol 2007 143 12 1493 9 10.1001/archderm.143.12.1493 18086997 (Pubitemid 350277763)
18. Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. N Bansback S Sizto H Sun S Feldman MK Willian A Anis, Dermatology 2009 219 3 209 18 10.1159/000233234 19657180
19. Efficacy and Tolerability of Biologic and Nonbiologic Systemic Treatments for Moderate-to-Severe Psoriasis: Meta-Analysis of Randomized Controlled Trials. J Schmitt Z Zhang G Wozel M Meurer W Kirch, Br J Dermatol 2008 159 3 513 26 10.1111/j.1365-2133.2008.08732.x 18627372
20. Pharmacoeconomic Evaluation of New Treatments: Efficacy Versus Effectiveness Studies? C Bombardier A Maetzel, Ann Rheum Dis 1999 58 Suppl 1 82 I85 10.1136/ard.58.2008.i82 10577979
21. Why We Need Observational Studies to Evaluate the Effectiveness of Health Care. N Black, BMJ 1996 312 7040 1215 8 8634569 (Pubitemid 26136714)
22. De Testimonio: on the Evidence for Decisions About the Use of Therapeutic Interventions. M Rawlins, Lancet 2008 20 9656 2152 61 372 10.1016/S0140- 6736(08)61930-3
23. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. N Woolacott VY Bravo N Hawkins A Kainth Z Khadjesari K Misso, et al. Health Technol Assess 2006 10 ii xvi 1 16948890
24. Large-scale observational studies of hypericum extracts in patients with depressive disorders - a systematic review. K Linde L Knuppel, Phytomedicine 2005 12 148 157 10.1016/j.phymed.2004.02.004 15693723 (Pubitemid 40174344)
25. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. E von Elm DG Altman M Egger SJ Pocock PC Gotzsche JP Vandenbroucke, Ann Intern Med 2007 147 8 573 7 17938396 (Pubitemid 351664504)
26. Tools for Assessing Quality and Susceptibility to Bias in Observational Studies in Epidemiology: a Systematic Review and Annotated Bibliography. S Sanderson ID Tatt JP Higgins, Int J Epidemiol 2007 36 3 666 76 10.1093/ije/dym018 17470488 (Pubitemid 47244573)
27. The Feasibility of Creating a Checklist for the Assessment of the Methodological Quality Both of Randomised and Non-Randomised Studies of Health Care Interventions. J. SH Downs N Black, Epidemiol Community Health 1998 52 6 377 84 10.1136/jech.52.6.377 (Pubitemid 28438523)
28. Quality of Life of Psoriasis Patients Before and After Balneo - or Balneophototherapy. S Tabolli A Calza C Di Pietro F Sampogna D Abeni, Yonsei Med J 2009 50 2 215 21 10.3349/ymj.2009.50.2.215 19430554
29. Effectiveness of Clobetasol Propionate Spray 0.05% Added to Other Stable Treatments: Add-on Therapy in the COBRA Trial. SR Feldman, Cutis 2007 80 5 Suppl 20 8 18154220
30. Relevance of the COBRA Trial in Current Psoriasis Practice. JY Koo, Cutis 2007 80 5 Suppl 4 11 18154218
31. The Evolving Role of Topical Treatments in Adjunctive Therapy for Moderate to Severe Plaque Psoriasis. M Lebwohl LE Colon, Cutis 2007 80 5 Suppl 29 40 18154221
32. Topical Monotherapy With Clobetasol Propionate Spray 0.05% in the COBRA Trial. A Menter, Cutis 2007 80 5 Suppl 12 9 18154219
33. Etanercept Improves Psoriatic Arthritis Patient-Reported Outcomes: Results From EDUCATE. EH Frankel BE Strober JJ Crowley DP Fivenson JM Woolley EB Yu HA Xia CF Chiou SR Stevens, Cutis 2007 79 4 322 6 17500381
34. Use of Etanercept for Psoriatic Arthritis in the Dermatology Clinic: the Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) Study. AB Gottlieb L Kircik D Eisen JM Jackson EE Boh BE Strober E Frankel HA Xia SR Stevens, J Dermatolog Treat 2006 17 6 343 52 10.1080/09546630600967166 17853307 (Pubitemid 46895587)
35. Clinical Characteristics of Psoriatic Arthritis and Psoriasis in Dermatologists' Offices. AB Gottlieb PJ Mease Mark J Jackson D Eisen Amy H Xia C Asare SR Stevens, J Dermatolog Treat 2006 17 5 279 87 10.1080/09546630600823369 17092858 (Pubitemid 44595016)
36. Reductions in Healthcare Resource Utilization in Psoriatic Arthritis Patients Receiving Etanercept Therapy: Results From the Educate Trial. AB Kimball JM Jackson JM Sobell EE Boh S Grekin EB Pharmd JM Woolley HA Xia CF Chiou SR Stevens, J Drugs Dermatol 2007 6 3 299 306 17373192
37. Tacalcitol Ointment for Long-Term Control of Chronic Plaque Psoriasis in Dermatological Practice. J Lambert C Trompke, Dermatology 2002 204 4 321 4 10.1159/000063376 12077538 (Pubitemid 34665161)
38. Efficacy and Safety of Etanercept in Psoriasis After Switching From Other Treatments: an Observational Study. A Mazzotta M Esposito A Costanzo S Chimenti, Am J Clin Dermatol 2009 10 5 319 24 10.2165/11310770-000000000-00000 19658444
39. Willingness to Pay and Time Trade-Off: Sensitive to Changes of Quality of Life in Psoriasis Patients? R Schiffner J Schiffner-Rohe M Gerstenhauer F Hofstadter M Landthaler W Stolz, Br J Dermatol 2003 148 6 1153 60 10.1046/j.1365-2133.2003.05156.x 12828743 (Pubitemid 36819214)
40. Differences in Efficacy Between Intention-to-Treat and Per-Protocol Analyses for Patients With Psoriasis Vulgaris and Atopic Dermatitis: Clinical and Pharmacoeconomic Implications. R Schiffner J Schiffner-Rohe M Gerstenhauer F Hofstadter M Landthaler W Stolz, Br J Dermatol 2001 144 6 1154 60 10.1046/j.1365-2133.2001.04234.x 11422035 (Pubitemid 34204205)
41. An Observation Study Evaluating the Efficacy of Tazarotene Plus Corticosteroid in Treating Plaque Psoriasis in Patients Switched From Treatment With Calcipotriene Corticosteroid. EA Tanghetti, Cutis 2000 66 6 Suppl 12 8 11147086
42. An Observation Study Evaluating the Treatment of Plaque Psoriasis With Tazarotene Gels, Alone and With an Emollient and/or Corticosteroid. EA Tanghetti, Cutis 2000 66 6 Suppl 4 11 11147088
43. Calcipotriol Solution for the Treatment of Scalp Psoriasis: Evaluation of Efficacy, Safety and Acceptance in 3,396 Patients. D Thaci W Daiber WH Boehncke R Kaufmann, Dermatology 2001 203 2 153 6 10.1159/000051731 11586015 (Pubitemid 34701576)
44. Quality of Life in Psoriasis Improves After Standardized Administration of Narrowband UVB Phototherapy. C Lim P Brown, Australas J Dermatol 2006 47 1 37 40 10.1111/j.1440-0960.2006.00220.x 16405481
45. Clinical Severity of Psoriasis in Last 20 Years of PUVA Study. T Nijsten CW Looman RS Stern, Arch Dermatol 2007 143 9 1113 21 10.1001/archderm.143.9.1113 17875871 (Pubitemid 47443362)
46. Cardiovascular Disease, Cancer, and Cause of Death in Patients With Psoriasis: 10 Years Prospective Experience in a Cohort of 1,380 Patients. RS Stern R Lange, J Invest Dermatol 1988 91 3 197 201 10.1111/1523-1747.ep12464847 3411140
47. Long-Term Use of Psoralens and Ultraviolet A for Psoriasis: Evidence for Efficacy and Cost Savings. RS Stern, J Am Acad Dermatol 1986 14 3 520 6 10.1016/S0190-9622(86)70066-2 3958270 (Pubitemid 16167271)
48. Long-Term Follow-Up of Skin Cancer in the PUVA-48 Cooperative Study. AB Forman HH Roenigk Jr WA Caro ML Magid, Arch Dermatol 1989 125 4 515 9 10.1001/archderm.125.4.515 2649011 (Pubitemid 19108963)
49. Skin Tumors in the European PUVA Study. Eight-Year Follow-Up of 1,643 Patients Treated With PUVA for Psoriasis. T Henseler E Christophers H Honigsmann K Wolff, J Am Acad Dermatol 1987 16 1 Pt 1 108 16 10.1016/S0190-9622(87)70010-3 3805379 (Pubitemid 17001986)
50. The Risk of Melanoma in Association With Long-Term Exposure to PUVA. RS Stern, J Am Acad Dermatol 2001 44 5 755 61 10.1067/mjd.2001.114576 11312420 (Pubitemid 32391161)
51. PUVA and Cancer Risk: the Swedish Follow-Up Study. B Lindelof B Sigurgeirsson E Tegner O Larko A Johannesson B Berne B Ljunggren T Andersson L Molin E Nylander-Lundqvist L Emtestam, Br J Dermatol 1999 141 1 108 12 10.1046/j.1365-2133.1999.02928.x 10417523 (Pubitemid 29333701)
52. Cancer Incidence Among Finnish Patients With Psoriasis Treated With Trioxsalen Bath PUVA. A Hannuksela E Pukkala M Hannuksela J Karvonen, J Am Acad Dermatol 1996 35 5 Pt 1 685 9 10.1016/S0190-9622(96)90721-5 8912561 (Pubitemid 26389465)
53. Medication Adherence and Health Care Costs Associated With Biologics in Medicaid-Enrolled Patients With Psoriasis. MJ Bhosle SR Feldman FT Camacho Timothy J Whitmire MC Nahata R Balkrishnan, J Dermatolog Treat 2006 17 5 294 301 10.1080/09546630600954594 17092860 (Pubitemid 44595018)
54. Utilization Pattern of Etanercept and Its Cost Implications in Moderate to Severe Psoriasis in a Managed Care Population. EQ Wu SR Feldman L Chen A Kaltenboeck AP Yu SR Gupta D Laitinen MK Willian, Curr Med Res Opin 2008 24 12 3493 501 10.1185/03007990802551057 19032131
55. Low Prescription Rate for Systemic Treatments in the Management of Severe Psoriasis Vulgaris and Psoriatic Arthritis in Dermatological Practices in Berlin and Brandenburg, Germany: Results From a Patient Registry. A Nast N Reytan S Rosumeck R Erdmann B Rzany, J Eur Acad Dermatol Venereol 2008 22 11 1337 42 10.1111/j.1468-3083.2008.02841.x 18624864
56. Psoriatic Arthritis. Historical Background and Epidemiology. T O'Neill AJ Silman, Baillieres Clin Rheumatol 1994 8 2 245 61 8076386 (Pubitemid 24189838)
57. The Impact of Psoriasis on Health Care Costs and Patient Work Loss. JF Fowler MS Duh L Rovba S Buteau L Pinheiro F Lobo J Sung JJ Doyle A Swensen DA Mallett G Kosicki, J Am Acad Dermatol 2008 59 5 772 80 10.1016/j.jaad.2008.06. 043 19119095
58. National Registries of Systemic Treatment for Psoriasis and the European 'Psonet' Initiative. LL Lecluse L Naldi RS Stern PI Spuls, Dermatology 2009 218 4 347 56 10.1159/000183757 19077384
59. Reader's Guide to Critical Appraisal of Cohort Studies: 1. Role and Design. PA Rochon JH Gurwitz K Sykora M Mamdani DL Streiner S Garfinkel SL Normand GM Anderson, BMJ 2005 330 7496 895 7 10.1136/bmj.330.7496.895 15831878 (Pubitemid 40545694)
60. Reader's Guide to Critical Appraisal of Cohort Studies: 2. Assessing Potential for Confounding. M Mamdani K Sykora P Li SL Normand DL Streiner PC Austin PA Rochon GM Anderson, BMJ 2005 330 7497 960 2 10.1136/bmj.330.7497.960 15845982 (Pubitemid 40592320)
61. Readers Guide to Critical Appraisal of Cohort Studies: 3. Analytical Strategies to Reduce Confounding. SL Normand K Sykora P Li M Mamdani PA Rochon GM Anderson, BMJ 2005 330 7498 1021 3 10.1136/bmj.330.7498.1021 15860831 (Pubitemid 40604289)
62. Alefacept With Methotrexate for Treatment of Psoriatic Arthritis: Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study. PJ Mease K Reich, J Am Acad Dermatol 2009 60 3 402 11 10.1016/j.jaad.2008.09.050 19028407
63. Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression. PJ Mease AJ Kivitz FX Burch EL Siegel SB Cohen P Ory D Salonen J Rubenstein JT Sharp W Tsuji, Arthritis Rheum 2004 50 7 2264 72 10.1002/art.20335 15248226 (Pubitemid 38924405)
64. Clinical Experience Acquired With Raptiva (CLEAR) Trial in Patients With Moderate-to-Severe Plaque Psoriasis: Results From Extended Treatment in an International, Phase III, Placebo-Controlled Trial. W Sterry G Stingl RG Langley H Zacharie M Lahfa A Giannetti C Ferrandiz R Sinclair JH Saurat, J Dtsch Dermatol Ges 2006 4 11 947 56 10.1111/j.1610-0387.2006.06111.x 17081270
65. DANBIO: a Nationwide Registry of Biological Therapies in Denmark. ML Hetland, Clin Exp Rheumatol 2005 23 5 Suppl 39 205 S207 16273809
66. PsoReg - the Swedish Registry for Systemic Psoriasis Treatment. The Registry's Design and Objectives. M Schmitt-Egenolf, Dermatology 2007 214 2 112 7 17341858 (Pubitemid 46377234)
67. Clinical and Genetic Registries in Psoriatic Disease. DD Gladman P Rahman GG Krueger PJ Mease AA Qureshi JP Dutz U Lindqvist S Carneiro PS Helliwell I Ujfalussy AB Gottlieb F Behrens M Stahle, J Rheumatol 2008 35 7 1458 63 18609745 (Pubitemid 352000804)
68. Psoriasis Treatment With Etanercept and Efalizumab: Clinical Strategies Influencing Treatment Outcome. RJ Driessen MA Berends JB Boezeman PC Van De Kerkhof EM De Jong, Br J Dermatol 2008 158 5 1098 106 10.1111/j.1365-2133.2008. 08514.x 18384440 (Pubitemid 351521467)
69. Three-Year Registry Data on Biological Treatment for Psoriasis: the Influence of Patient Characteristics on Treatment Outcome. RJ Driessen JB Boezeman PC Van De Kerkhof EM De Jong, Br J Dermatol 2009 160 3 670 5 10.1111/j.1365-2133.2008.09019.x 19210502
70. Tacalcitol in the Treatment of Psoriasis Vulgaris: the Spanish Experience. M Lecha A Mirada S Lopez M Artes, J Eur Acad Dermatol Venereol 2005 19 4 414 7 10.1111/j.1468-3083.2005.01099.x 15987284 (Pubitemid 40946091)
71. Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis. Evidence From the Psocare Project. L Naldi A Addis S Chimenti A Giannetti M Picardo C Tomino M Maccarone L Chatenoud P Bertuccio E Caggese R Cuscito, Dermatology 2008 217 4 365 73 10.1159/000156599 18810241
72. Risk of Malignancies in Psoriasis Patients Treated With Cyclosporine: a 5 y Cohort Study. CF Paul VC Ho C McGeown E Christophers B Schmidtmann JC Guillaume V Lamarque L Dubertret, J Invest Dermatol 2003 120 2 211 6 10.1046/j.1523-1747.2003.12040.x 12542524 (Pubitemid 36513069)
73. No Long-Term Changes in Psoriasis Severity and Quality of Life Following Climate Therapy. AK Wahl C Mork BA Cooper G Padilla, J Am Acad Dermatol 2005 52 4 699 701 10.1016/j.jaad.2005.01.117 15793527 (Pubitemid 40585447)
74. The Comparative One-Year Performance of Anti-Tumor Necrosis Factor Alpha Drugs in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Results From a Longitudinal, Observational, Multicenter Study. MS Heiberg W Koldingsnes K Mikkelsen E Rodevand C Kaufmann P Mowinckel TK Kvien, Arthritis Rheum 2008 59 2 234 40 10.1002/art.23333 18240258 (Pubitemid 351272960)
75. The Comparative Effectiveness of Anti-TNF Therapy and Methotrexate in Patients With Psoriatic Arthritis: 6 Month Results From a Longitudinal, Observational, Multicentre Study. MS Heiberg C Kaufmann E Rodevand K Mikkelsen W Koldingsnes P Mowinckel TK Kvien, Ann Rheum Dis 2007 66 8 1038 42 10.1136/ard.2006.064808 17213251 (Pubitemid 47122316)
76. Efficacy and Tolerability of Anti-Tumour Necrosis Factor Therapy in Psoriatic Arthritis Patients: Results From the South Swedish Arthritis Treatment Group Register. LE Kristensen A Gulfe T Saxne P Geborek, Ann Rheum Dis 2008 67 3 364 9 10.1136/ard.2007.073544 17644547 (Pubitemid 351281272)
77. Rapid and Sustained Health Utility Gain in Anti-TNF Treated Inflammatory Arthritis. Observational Data During Seven Years in Southern Sweden. A Gulfe LE Kristensen T Saxne LT Jacobsson IF Petersson P Geborek, Ann Rheum Dis 2009
78. Etanercept, Infliximab, and Leflunomide in Established Rheumatoid Arthritis: Clinical Experience Using a Structured Follow Up Programme in Southern Sweden. P Geborek M Crnkic IF Petersson T Saxne, Ann Rheum Dis 2002 61 9 793 8 10.1136/ard.61.9.793 12176803
79. Impact of Concomitant DMARD Therapy on Adherence to Treatment With Etanercept and Infliximab in Rheumatoid Arthritis. Results From a Six-Year Observational Study in Southern Sweden. LE Kristensen T Saxne JA Nilsson P Geborek, Arthritis Res Ther 2006 8 6 174 10.1186/ar2084 17121678
80. A. Life-Table Analysis of Cyclosporin A Treatment in Psoriatic Arthritis: Comparison With Other Disease-Modifying Antirheumatic Drugs. A Spadaro E Taccari B Mohtadi V Riccieri F Sensi Zoppini, Clin Exp Rheumatol 1997 15 6 609 14 9444416 (Pubitemid 27501646)
81. Persistence With Anti-Tumour Necrosis Factor Therapies in Patients With Psoriatic Arthritis: Observational Study From the British Society of Rheumatology Biologics Register. AA Saad DM Ashcroft KD Watson KL Hyrich PR Noyce DP Symmons, Arthritis Res Ther 2009 11 2 52 10.1186/ar2670 19356232
82. Rates of New-Onset Psoriasis in Patients With Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Alpha Therapy: Results From the British Society for Rheumatology Biologics Register. MJ Harrison WG Dixon KD Watson Y King R Groves KL Hyrich DP Symmons, Ann Rheum Dis 2009 68 2 209 15 10.1136/ard.2007.087288 18385277
83. British Society for Rheumatology Biologics Register. A Silman D Symmons DG Scott I Griffiths, Ann Rheum Dis 2003 62 Suppl 2 i28 9 ii28-ii29. 14532144
84. A Prospective Evaluation of the Cost of Psoriasis in Spain (EPIDERMA Project: Phase II). JM Carrascosa R Pujol E Dauden JM Hernanz-Hermosa X Bordas JA Smandia C Ferrandiz, J Eur Acad Dermatol Venereol 2006 20 7 840 5 16898908 (Pubitemid 44102918)
85. Significance of the Stigmatization Experience of Psoriasis Patients: a 1-Year Follow-Up of the Illness and Its Psychosocial Consequences in Men and Women. G Schmid-Ott HW Kunsebeck B Jager U Sittig N Hofste R Ott P Malewski F Lamprecht, Acta Derm Venereol 2005 85 1 27 32 10.1080/000155550410021583 15848987 (Pubitemid 40254676)
86. Improved Survival in Psoriatic Arthritis With Calendar Time. Y Ali BD Tom CT Schentag VT Farewell DD Gladman, Arthritis Rheum 2007 56 8 2708 14 10.1002/art.22800 17665458 (Pubitemid 47237289)
87. Prevalence of Malignancy in Psoriatic Arthritis. S Rohekar BD Tom A Hassa CT Schentag VT Farewell DD Gladman, Arthritis Rheum 2008 58 1 82 7 10.1002/art.23185 18163513
88. Functional Assessment of Chronic Illness Therapy-Fatigue Scale Is Valid in Patients With Psoriatic Arthritis. V Chandran S Bhella C Schentag DD Gladman, Ann Rheum Dis 2007 66 7 936 9 10.1136/ard.2006.065763 17324972 (Pubitemid 46999797)
89. Clinical Indicators of Progression in Psoriatic Arthritis: Multivariate Relative Risk Model. DD Gladman VT Farewell C Nadeau, J Rheumatol 1995 22 4 675 9 7791162
90. Mortality Studies in Psoriatic Arthritis: Results From a Single Outpatient Center. II. Prognostic Indicators for Death. DD Gladman VT Farewell K Wong J Husted, Arthritis Rheum 1998 41 6 1103 10 10.1002/1529-0131(199806)41: 6<1103::AID-ART183.0.CO;2-N 9627021 (Pubitemid 28265412)
91. Progression in Psoriatic Arthritis: Role of Time Varying Clinical Indicators. DD Gladman VT Farewell, J Rheumatol 1999 26 11 2409 13 10555902 (Pubitemid 29528983)
92. Remission in Psoriatic Arthritis. DD Gladman EN Hing CT Schentag RJ Cook, J Rheumatol 2001 28 5 1045 8 11361187 (Pubitemid 32422587)
93. Description and Prediction of Physical Functional Disability in Psoriatic Arthritis: a Longitudinal Analysis Using a Markov Model Approach. JA Husted BD Tom VT Farewell CT Schentag DD Gladman, Arthritis Rheum 2005 53 3 404 9 10.1002/art.21177 15934101 (Pubitemid 40799880)
94. Mortality Studies in Psoriatic Arthritis: Results From a Single Outpatient Clinic. I. Causes and Risk of Death. K Wong DD Gladman J Husted JA Long VT Farewell, Arthritis Rheum 1997 40 10 1868 72 10.1002/art.1780401021 9336423 (Pubitemid 27452539)
95. A Prospective, Clinical and Radiological Study of Early Psoriatic Arthritis: an Early Synovitis Clinic Experience. D Kane L Stafford B Bresnihan O FitzGerald, Rheumatology (Oxford) 2003 42 12 1460 8 10.1093/rheumatology/keg384 14523223 (Pubitemid 37508919)
96. A Classification Study of Clinical Subsets in an Inception Cohort of Early Psoriatic Peripheral Arthritis - 'DIP or Not DIP Revisited'. D Kane L Stafford B Bresnihan O FitzGerald, Rheumatology (Oxford) 2003 42 12 1469 76 10.1093/rheumatology/keg445 12867577 (Pubitemid 37508920)
97. The Swedish Early Psoriatic Arthritis Register - 2-Year Followup: a Comparison With Early Rheumatoid Arthritis. UR Lindqvist GM Alenius T Husmark E Theander G Holmstrom PT Larsson, J Rheumatol 2008 35 4 668 73 18278834 (Pubitemid 351500064)
98. Development and Early Experiences of a Swedish Psoriatic Arthritis Register. B Svensson G Holmstrom U Lindqvist, Scand J Rheumatol 2002 31 4 221 5 10.1080/030097402320318413 12369654 (Pubitemid 34971879)